Elevation of p-NR2AS1232 by Cdk5/p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model

Neurobiology of Disease

Volumn 43, Issue 2, 2011, Pages 455-464

  Chen, Jie ^a   Miao, Yanying ^a   Wang, Xiao Han ^a   Wang, Zhongfeng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cdk5 p35; Glaucoma; Inner retina; NMDA receptor; Roscovitine

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CYCLIN DEPENDENT KINASE 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; PROTEIN P35; ROSCOVITINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GLAUCOMA; MALE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; RETINA GANGLION CELL;

ANIMALS; APOPTOSIS; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; GLAUCOMA; MALE; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RETINAL DEGENERATION; RETINAL GANGLION CELLS; UP-REGULATION;

EID: 79958229321     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.04.019     Document Type: Article

References (77)

1. Borghi R., et al. Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy. Neurology 2002, 58:589-592.
2. Bu B., et al. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 2002, 22:6515-6525.
3. Calzada J.I., et al. Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers. Neurochem. Res. 2002, 27:79-88.
4. Chae T., et al. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 1997, 18:29-42.
5. Chaudhary P., et al. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 1998, 792:154-158.
6. Chen J., Wang Z. Roles of cycline-dependent kinase 5 in central nervous system development and neurodegenerative diseases. Acta Physiol. Sin. 2010, 62:295-308.
7. Chen L., et al. Inwardly rectifying potassium channels in rat retinal ganglion cells. Eur. J. Neurosci. 2004, 20:956-964.
8. Chen S., Diamond J.S. Synaptically released glutamate activates extrasynaptic NMDA receptors on cells in the ganglion cell layer of rat retina. J. Neurosci. 2002, 22:2165-2173.
9. Chen Y.N., et al. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists. Brain Res. 2007, 1148:28-37.
10. Cheung Z.H., et al. Cyclin-dependent kinase 5 supports neuronal survival through phosphorylation of Bcl-2. J. Neurosci. 2008, 28:4872-4877.
11. Choi D.W. Ionic dependence of glutamate neurotoxicity. J. Neurosci. 1987, 7:369-379.
12. Cruz J.C., Tsai L.H. A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr. Opin. Neurobiol. 2004, 14:390-394.
13. Dhavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2001, 2:749-759.
14. Doh S.H., et al. Retinal ganglion cell death induced by endoplasmic reticulum stress in a chronic glaucoma model. Brain Res. 2010, 1308:158-166.
15. Dreyer E.B., et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 1996, 114:299-305.
16. Fletcher E.L., et al. Synaptic localization of NMDA receptor subunits in the rat retina. J. Comp. Neurol. 2000, 420:98-112.
17. Gavrieli Y., et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992, 119:493-501.
18. Guo L., et al. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest. Ophthalmol. Vis. Sci. 2005, 46:175-182.
19. Guo L., et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest. Ophthalmol. Vis. Sci. 2006, 47:626-633.
20. Hare W.A., et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest. Ophthalmol. Vis. Sci. 2004, 45:2640-2651.
21. Hayashi T., et al. DNA fragmentation precedes aberrant expression of cell cycle-related protein in rat brain after MCA occlusion. Neurol. Res. 1999, 21:695-698.
22. Hilton G.D., et al. Roscovitin reduces neuronal loss, glial activation and neurological deficits after brain trauma. J. Cereb. Blood Flow Metab. 2008, 28:1845-1859.
23. Hirooka K., et al. Developmental alteration of the expression and kinase activity of cyclin-dependent kinase 5 (Cdk5)/p35nck5a in the rat retina. J. Neurochem. 1996, 67:2478-2483.
24. Hitchings R.A. Selective ganglion cell death in glaucoma. Br. J. Ophthalmol. 2000, 84:678-679.
25. Hosokawa T., et al. Enhanced activation of Ca2+/calmodulin-dependent protein kinase II upon downregulation of cyclin-dependent kinase 5-p35. J. Neurosci. Res. 2006, 84:747-754.
26. Ju W.K., et al. Glutamate receptor activation triggers OPA1 release and induces apoptotic cell death in ischemic rat retina. Mol. Vis. 2008, 14:2629-2638.
27. Kerokoski P., et al. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35. Brain Res. Mol. Brain Res. 2002, 106:50-56.
28. Ko J., et al. P35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 2001, 21:6758-6771.
29. Lee K.Y., et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 1999, 34:21-29.
30. Lee M.S., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360-364.
31. Lee S.Y., et al. Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. Proc. Natl. Acad. Sci. USA 2004, 101:546-551.
32. Lefevre K., et al. Involvement of cyclin-dependent kinases in axotomy-induced retinal ganglion cell death. J. Comp. Neurol. 2002, 447:72-81.
33. Leitch A.E., et al. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br. J. Pharmacol. 2009, 158:1004-1016.
34. Levin L.A. Retinal ganglion cells and neuroprotection for glaucoma. Surv. Ophthalmol. 2003, 48(Suppl 1):S21-S24.
35. Levkovitch-Verbin H., et al. Measurement of amino acid levels in the vitreous humor of rats after chronic intraocular pressure elevation or optic nerve transection. J. Glaucoma 2002, 11:396-405.
36. Li B.S., et al. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J. Biol. Chem. 2003, 278:35702-35709.
37. Li B.S., et al. Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc. Natl. Acad. Sci. USA 2001, 98:12742-12747.
38. Lipton S.A. Retinal ganglion cells, glaucoma and neuroprotection. Prog. Brain Res. 2001, 131:712-718.
39. Luo X.G., et al. The selective vulnerability of retinal ganglion cells in rat chronic ocular hypertension model at early phase. Cell. Mol. Neurobiol. 2009, 29:1143-1151.
40. Martin K.R., et al. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest. Ophthalmol. Vis. Sci. 2002, 43:2236-2243.
41. Morabito M.A., et al. Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynaptic density protein PSD-95 in neurons. J. Neurosci. 2004, 24:865-876.
42. Naka M., et al. Reduced expression of aquaporin-9 in rat optic nerve head and retina following elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2010, 51:4618-4626.
43. Neufeld A.H., et al. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc. Natl. Acad. Sci. USA 1999, 96:9944-9948.
44. Nguyen M.D., et al. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J. Neurosci. 2003, 23:2131-2140.
45. Novelli A., et al. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451:205-212.
46. Nucci C., et al. Neurochemical evidence to implicate elevated glutamate in the mechanisms of high intraocular pressure (IOP)-induced retinal ganglion cell death in rat. Neurotoxicology 2005, 26:935-941.
47. Oka T., et al. Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. J. Neurosci. Res. 2006, 83:1342-1351.
48. Patrick G.N., et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
49. Qiu W., et al. A glycine site-specific NMDA receptor antagonist protects retina ganglion cells from ischemic injury by modulating apoptotic cascades. J. Cell. Physiol. 2010, 223:819-826.
50. Quigley H.A., et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 1995, 36:774-786.
51. Resnikoff S., et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 2004, 82:844-851.
52. Salt T.E., Cordeiro M.F. Glutamate excitotoxicity in glaucoma: throwing the baby out with the bathwater?. Eye 2006, 20:730-731. author reply 731-732.
53. Sawada A., Neufeld A.H. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp. Eye Res. 1999, 69:525-531.
54. Schmidt K.G., et al. Ischemia and hypoxia, An attempt to explain the different rates of retinal ganglion cell death in glaucoma. Ophthalmologe 2004, 101:1071-1075.
55. Seki M., Lipton S.A. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog. Brain Res. 2008, 173:495-510.
56. Shen Y., et al. N-methyl-D-aspartate receptors in the retina. Mol. Neurobiol. 2006, 34:163-179.
57. Smith P.D., et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2003, 100:13650-13655.
58. Tang D., et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem. 1995, 270:26897-26903.
59. Thoreson W.B., Witkovsky P. Glutamate receptors and circuits in the vertebrate retina. Prog. Retin. Eye Res. 1999, 18:765-810.
60. Tomizawa K., et al. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J. Neurosci. 2002, 22:2590-2597.
61. Tsai L.H., et al. P35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423.
62. Ullian E.M., et al. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol. Cell. Neurosci. 2004, 26:544-557.
63. Vorwerk C.K., et al. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest. Ophthalmol. Vis. Sci. 2000, 41:3615-3621.
64. Wang C.X., et al. Cyclin-dependent kinase-5 prevents neuronal apoptosis through ERK-mediated upregulation of Bcl-2. Cell Death Differ. 2006, 13:1203-1212.
65. Wang J., et al. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 2003, 6:1039-1047.
66. Wei F.Y., et al. Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stability. J. Neurochem. 2005, 93:502-512.
67. Weinreb R.N., Khaw P.T. Primary open-angle glaucoma. Lancet 2004, 363:1711-1720.
68. Weishaupt J.H., et al. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol. Cell. Neurosci. 2003, 24:489-502.
69. Woldemussie E., et al. Neuroprotective effect of memantine in different retinal injury models in rats. J. Glaucoma 2002, 11:474-480.
70. Wu J., et al. Neuroprotective effect of upregulated sonic Hedgehog in retinal ganglion cells following chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2010, 51:2986-2992.
71. Yan Z., et al. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. J. Physiol. Lond 2002, 540:761-770.
72. Yang H., et al. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest. Ophthalmol. Vis. Sci. 2009, 50:5800-5804.
73. Yang X.L. Characterization of receptors for glutamate and GABA in retinal neurons. Prog. Neurobiol. 2004, 73:127-150.
74. Yu S., et al. A rat model of glaucoma induced by episcleral vein ligation. Exp. Eye Res. 2006, 83:758-770.
75. Zhang J., Diamond J.S. Distinct perisynaptic and synaptic localization of NMDA and AMPA receptors on ganglion cells in rat retina. J. Comp. Neurol. 2006, 498:810-820.
76. Zhang Q., et al. Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev. Biol. 1997, 183:222-233.
77. Zhao W.J., et al. Melatonin potentiates glycine currents through a PLC/PKC signaling pathway in rat retinal ganglion cells. J. Physiol. Lond 2010, 588:2605-2619.